Current recommendations for the molecular evaluation of newly diagnosed holoprosencephaly patients. by Pineda-Alvarez, Daniel et al.
Current recommendations for the molecular evaluation
of newly diagnosed holoprosencephaly patients.
Daniel Pineda-Alvarez, Christe`le Dubourg, Ve´ronique David, Erich Roessler,
Maximilian Muenke
To cite this version:
Daniel Pineda-Alvarez, Christe`le Dubourg, Ve´ronique David, Erich Roessler, Maximilian
Muenke. Current recommendations for the molecular evaluation of newly diagnosed holo-
prosencephaly patients.. American Journal of Medical Genetics Part C: Seminars in Medical
Genetics, Wiley, 2010, 154C (1), pp.93-101. <10.1002/ajmg.c.30253>. <inserm-00462036>
HAL Id: inserm-00462036
http://www.hal.inserm.fr/inserm-00462036
Submitted on 11 Mar 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 
 
1 
Our current recommendations for the molecular 
evaluation of newly diagnosed holoprosencephaly 
patients 
 
DANIEL E. PINEDA-ALVAREZ, CHRISTÈLE DUBOURG, VÉRONIQUE 
DAVID, ERICH ROESSLER AND MAXIMILIAN MUENKE* 
 
Dr. Pineda-Alvarez is a Colombian trained medical graduate who is currently, a 
Clinical Molecular Genetics fellow in the Medical Genetics Branch, National Human 
Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. 
Dr. Roessler is a faculty member in the Medical Genetics Branch, National 
Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.  
His research interests include malformations of the forebrain associated with 
holoprosencephaly (HPE) as well as disturbances in organ sidedness, or laterality. 
Dr. Muenke is the Branch Chief of the Medical Genetics Branch. His research 
interests include HPE, craniofacial malformation syndromes, and Attention Deficit 
Hyperactivity Disorder (ADHD). 
*Correspondence to: Maximilian Muenke, Medical Genetics Branch, National Human 
Genome Research Institute, National Institutes of Health, 35 Convent Drive, MSC 3717, 
American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 
 
2 
Building 35, Room 1B-203, Bethesda, MD 20892-3717, Tel.:(301) 402-8167, Fax.:(301) 
480-7876, E-mail:  mamuenke@mail.nih.gov 
American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 
 
3 
ABSTRACT 
Holoprosencephaly (HPE) is the most common structural malformation of the developing 
forebrain in humans and is typically characterized by different degrees of hemispheric 
separation that are often accompanied by similarly variable degrees of craniofacial and 
midline anomalies.  HPE is a classic example of a complex genetic trait with “pseudo”-
autosomal dominant transmission showing incomplete penetrance and variable 
expressivity.  Clinical suspicion of HPE is typically based upon compatible craniofacial 
findings, the presence of developmental delay or seizures, or specific endocrinological 
abnormalities, which is then followed up by confirmation with brain imaging.  Once a 
clinical diagnosis is made, a thorough genetic evaluation is necessary. This usually 
includes analysis of chromosomes by high-resolution karyotyping, clinical assessment to 
rule-out well recognized syndromes that may cause HPE (e.g. Pallister-Hall syndrome, 
Smith-Lemli-Opitz syndrome and others), and molecular studies of the most common 
HPE associated genes (e.g. SHH, ZIC2, SIX3, and TGIF).  In this review, we will provide 
our current step-by-step recommendations that are medically indicated for the genetic 
evaluation of patients with newly diagnosed HPE.  Moreover, we will provide a brief 
review of the several available methods used in the molecular diagnostics of HPE and 
describe the advantages and limitations of both currently available and future tests as they 
relate to high throughput screening, cost, and the results that they may provide.  
 
KEY WORDS: holoprosencephaly, HPE, disease genes, multi-factorial inheritance, 
molecular diagnostics 
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INTRODUCTION 
Holoprosencephaly (HPE) is most common disorder of the developing forebrain 
in humans, and it occurs with a frequency of 1:250 conceptuses [Matsunaga and Shiota, 
1977] and 1:10-16,000 live births [Roach et al., 1975].  The HPE phenotypic spectrum 
results from failure of the forebrain to cleave into two hemispheres.  Different degrees of 
hemispheric separation, ranging from the classically described alobar form, to semilobar, 
lobar and middle-interhemispheric variant (MIHV) describe the anatomically 
distinguishable forms of HPE.  The mildest end of the spectrum includes subtle midline 
brain anomalies. These phenotypes are often accompanied by a broad spectrum of 
craniofacial differences, ranging from the most severe form with cyclopia (one eye) or 
synophthalmia (two fused eyes) with a proboscis (nose-like appendage), to less severe 
forms with hypotelorism, mid-face hypoplasia or a single maxillary central incisor (SCI) 
[Cohen, 2006; Dubourg et al., 2007; Muenke and Beachy, 2000; reviewed in Solomon et 
al., this issue].  The occurrence and manifestations of HPE are influenced by both genetic 
causes and environmental risk factors.  In cases where a specific gene is known to be 
causative, it is inherited as a typical complex trait with incomplete penetrance and 
variable expressivity.  The basis of these phenotypic differences is largely unknown but 
likely reflects measured and unmeasured genetic and environmental components 
[Solomon et al., 2009]. 
 
CYTOGENETIC ALTERATIONS AND MUTATIONS OF DEVELOPMENTAL 
GENES ARE THE MOST COMMON KNOWN CAUSES OF HPE 
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It is estimated that the etiology of HPE is due to cytogenetic anomalies in 30-50% 
of individuals, is associated with well recognized syndromes (e.g. Smith-Lemli-Opitz 
syndrome (SLOS)) in ~25%, is due to either environmental causes and/or unknown 
genetic alterations in ~10-15%, and is caused by mutations in established HPE gene(s) 
~5-10% [Bullen et al., 2001; Ong et al., 2007; Dubourg et al., 2007; Roessler et al., 
2009a].  Additional risk factors that may act alone or in concert with genetic alterations 
include the use of retinoids, statins, or alcohol during pregnancy, alterations in the 
biosynthesis of cholesterol, and pre-existing or gestational diabetes [Cohen and Shiota, 
2002]. 
Mutations in at least 12 genes have been detected in patients with HPE, however, 
there is significant variability in the observed mutation rate of each gene (see below).  
Therefore, our current recommendations will reflect those genes with the highest degree 
of clinical utility for study, and we will propose which genes are best left to research 
applications.  The most common HPE genes were identified as mutational targets within 
loci defined by chromosomal rearrangements [Dubourg et al., 2004; Muenke and Beachy, 
2000].  Among the best characterized HPE genes are SHH [Roessler et al., 1996], ZIC2 
[Brown et al., 1998], SIX3 [Wallis et al., 1999], TGIF [Gripp et al., 2000], GLI2 
[Roessler et al., 2003],  PATCHED-1 [Ming et al., 2002], and DISP1 [Roessler et al., 
2009c], and others.  Most commercial and research laboratories only screen the first four 
genes (the named HPE loci 2-5) for mutations on a routine basis.  Micro-deletions and 
micro-duplications have been suggested to play important roles given that some of these 
alterations occur in the vicinity of known HPE genes [Bendavid et al., 2009]. 
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Currently, there are still a large proportion of individuals with non-syndromic and 
non-chromosomal HPE (~75% of patients) in which no specific genetic cause can be 
identified [Wallis and Muenke, 2000].  The general consensus regarding the etiology of 
HPE is that the molecular interactions and pathways are complex [Monuki, 2007], 
consistent with the theory that a large number of loci or genetic factors are yet to be 
indentified and more fully understood.  The primary goal of this review is to describe our 
current recommendations for molecular genetics testing of patients with newly diagnosed 
HPE, the types of strategies for evaluation that are currently used, what tests are likely to 
be of use in the future, and the advantages and limitations of these technologies. 
 
OUR CURRENT EVALUATION STRATEGY 
As described in Table I, methods such as single strand conformational 
polymorphism (SSCP) and denaturing High Performance Liquid Chromatography 
(DHPLC) have been used in the past as effective screening methods [Brown et al., 1998; 
Gripp et al., 2000; Roessler et al., 1996; Wallis et al., 1999].  However, disadvantages of 
SSCP and DHPLC include their comparatively low sensitivity and the exposure of the 
laboratory environment to radioactivity (SSCP) and the requirement of volatile chemicals 
to perform analysis (DHPLC) [O'Donovan et al., 1998; Orita et al., 1989].  New 
technologies, such as next generation platforms, offer the potential for more 
comprehensive analysis of a larger number of genes with even greater sensitivity and 
specificity (see below).  
 The clinical diagnosis of HPE is confirmed by a combination of physical 
examination, family history, and brain imaging (MRI, CT, or ultrasound, etc.).  Once 
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HPE is confirmed, we recommend that parents be invited to participate in the subsequent 
genetics work-up in order to allow for a more complete family-based evaluation in the 
setting of a positive cytogenetic or molecular finding.  Parental participation is also 
beneficial in terms of the broader goal of fostering research in the field of HPE research 
even if the given test results in their particular case are unrevealing.  Our experiences 
over the past decade have proven that the value of cooperation amongst multiple 
international testing centers goes beyond simply being able to share methodologies and 
testing strategies, but that the sharing of patient data and test samples enhances our 
likelihood of identifying additional HPE genes in the future.  
As shown in Figure 1, we propose a general strategy for the genetic evaluation of 
a newly diagnosed patient with HPE.  Holoprosencephaly is usually diagnosed clinically 
based upon specific phenotypic features (described above) [Cohen, 2006; Dubourg et al., 
2007; Orioli and Castilla, 2007], which typically must then be confirmed with brain 
imaging in order to fully characterize the anomaly [Hahn and Plawner, 2004].  A 
comprehensive evaluation of a patient with HPE should typically begin with cytogenetic 
studies, including a high-resolution karyotype with a minimum of 550 band resolution, 
given that ~40-50% of patients will have a chromosomal anomaly [Cohen, 2006; Orioli 
and Castilla, 2007]. In selected patients, medically indicated studies should then be done 
to rule out syndromes that might cause HPE (e.g. 7-dehydro-cholesterol levels elevated in 
SLOS).  Finally, in all non-syndromic patients found to have normal chromosomes, 
molecular analysis should be performed for the most common genes implicated in HPE: 
SHH, ZIC2, SIX3 and TGIF [Dubourg et al., 2004; Wallis and Muenke, 2000].   
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It is at the initial evaluation of a proband that it is most appropriate for the 
primary care giver to assess the willingness of the parents to participate in research in 
HPE, both by enrolling their child in a research study and by providing samples of their 
own blood for parallel studies.  Analysis of parental samples will further be important for 
the interpretation of the proband’s test results and for future genetic counseling, whether 
or not a cytogenetic or molecular diagnosis is immediately established.  The strongest 
predictors of the pathogenicity of new alterations relates to whether the changes are de 
novo gross cytogenetic, occult microgenetic, or mutations [reviewed in Roessler and 
Muenke in this issue]. In the broader research context, the accumulation of a diverse set 
of parent-child trios allows for future studies to address new genetic associations, 
modifier screens, and other methods aimed at better understanding how genetic 
interactions and genetic variations may influence the variable penetrance and expressivity 
of HPE traits.  Hence, the participation of parents in the molecular evaluation of their 
children can have both direct and indirect benefits for HPE research.  
For the above patients who have an abnormal karyotype, the cytogenetic findings 
should be correlated with the clinical phenotype and the underlying mechanism involved. 
For example, well recognized trisomies in chromosomes 13 and 18 or other 
rearrangements that may disrupt one of the major genes implicated in HPE, such as SHH 
or ZIC2, and thus contribute to the etiology of HPE [Dubourg et al., 2007].  Other 
chromosomal rearrangements can also occur [see Roessler and Muenke, this issue], 
however currently there is little proof of the pathogenicity for the majority of them.  New 
technologies, controlled population genetics, and functional studies should allow us to 
further expand our knowledge.  Again, parental studies are important to define whether 
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the anomaly is segregating through the family or if it is a de novo event.  A more in-depth 
molecular analysis of the chromosomal breakpoints, using DNA sequencing or array-
CGH, can be important given that, the vicinity of the breakpoints produces unstable DNA 
with deletions and duplications frequently occurring beyond the particular locus.  This 
additional research will allow for better characterization of the genetic alterations and 
phenotypic correlations, which may be helpful for genetic counseling purposes. 
For the patients with a normal karyotype, DNA sequencing analysis should be 
performed for the most commonly identified genes associated with HPE.  In general, 
mutations in SHH are present in ~12% of affected patients [Roessler et al., 2009a], ZIC2 
in ~9% [Roessler et al., 2009b], and SIX3 in ~5% [Lacbawan et al., 2009].  Given the 
high detection rate of likely pathologic mutations, we consider these genes to be essential 
for a first line medical assessment.  Other genes have been described to be associated 
with HPE, such as TGIF (altered in ~1% of patients) [Gripp et al., 2000; Wallis and 
Muenke, 2000], GLI2 (~1%) [Roessler et al., 2003], PATCHED-1 [Ming et al., 2002], 
DISP1 [Roessler et al., 2009c] , FOXH1, NODAL [Roessler et al., 2009d], and others.  
However, at the present time, we recommend that these latter genes with low mutation 
frequency rates among HPE patients be tested only in select cases, or that they be referred 
to specialized testing centers with the requisite expertise. 
One example of a specialized situation that calls for testing of GLI2 is when 
abnormalities occur in the development of the pituitary gland, in the context of variable 
brain and craniofacial anomalies consistent with the broad spectrum of HPE [Roessler et 
al., 2003; Roessler et al., 2005].  Likewise, other genes have also been shown to be 
associated with characteristic brain and craniofacial abnormalities [Solomon et al., this 
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issue; Muenke Lab unpublished data].  In the special case where a specific phenotype is 
present, molecular analysis of the associated locus is considered medically indicated.  
However, we still strongly encourage enrollment in research studies given that additional 
genetic and/or environmental co-factors may also be playing a role, even when a 
mutation is present in a well-characterized gene. 
From our current molecular diagnostic perspective, exonic mutational analysis via 
bi-directional DNA sequencing remains the gold standard.  Both pay-for-service and free 
research options are available and give comparable results.  Independently of where 
patients elect to do their molecular diagnostic test, we recommend that clinicians 
encourage patients to freely enroll in a HPE research study.  For example, in the consent 
process for research into HPE and related brain disorders at the National Institutes of 
Health (NIH), we offer clear opt-out provisions for future research results that empower 
parents to set limits on the results that they wish to obtain now, and those generated by 
future studies.  Likewise, we also recommend families to join support groups such as 
“Families for HoPE,” which will help them to overcome the difficulties of management 
of patients with the disorder. 
 When a novel mutation is identified in a proband, such as, a single nucleotide 
change, insertion, duplication, deletion or a frame-shift mutation, parental samples should 
subsequently be tested to assess whether the mutation is segregating in the family 
(familial HPE) [Solomon et al., 2009] or a de novo variant.  In general, de novo mutations 
are more likely to be pathogenic based on functional studies [Domené et al., 2008].  
However, a large proportion of patients have unique mutations that are family-specific 
that can make it very difficult to predict the likely consequences [Roessler et al., 2009a].  
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Therefore, continued cooperation with research centers can often result in the 
development of functional tests for novel sequence variants that can clarify the nature of 
such alterations. 
 In order to better identify which genetic variants are truly pathogenic, the 
identified variants must be correlated with their predicted or experimentally determined 
residual function.  Computerized prediction algorithms may be used, however they may 
be inconclusive; therefore, highly specialized functional studies based on animal models, 
cellular models and conservation analyses among vertebrate species are typically 
required. Functional consequences of changes in SIX3 [Domené et al., 2008], SHH 
[Roessler et al., 2009a], ZIC2 [Roessler et al., 2009b], and TGIF [El-Jaick et al., 2007], 
have been well illustrated [reviewed in Roessler and Muenke, this issue].  
Not all variants among the HPE genes are obvious loss-of-function. Although 
nucleotide changes occurring in very conserved regions of the genome are more likely to 
cause defects through loss–of-function, further analyses are frequently necessary to 
determine their precise effects [Kryukov et al., 2007].  Importantly, there is also 
increasing evidence that gene regulatory elements and non-coding portions of HPE genes 
can play an important role in disease causation and would be missed by most traditional 
diagnostic strategies [Jeong et al., 2008]. 
Local genetic counseling, facilitated by the expertise of tertiary care centers and 
patient groups, should be offered to families whether results of the genetic tests are 
negative or positive.  This counseling should be guided by state-of-the-art evidence to 
help to interpret the results and their limitations.  When there is inconclusive evidence 
about the effect of a given variant, it should be made clear to the family that the effect is 
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uncertain.  As noted previously, this is another strong case for participation in research 
investigations in both mutation positive and mutation negative cases. 
 
PAST, PRESENT AND FUTURE METHODS AND THEIR IMPLICATIONS 
In Table I, we present the advantages and disadvantages of several methods that 
have been used and that are being proposed for the molecular study of HPE.  In the past, 
SSCP and DHPLC have been used to screen for mutations in patients.  SSCP was initially 
the best way to pre-screen individuals for variants for a given DNA product, however it 
was not an ideal technique given that the radioactive materials required special handling 
and training and constituted a potential hazard for the laboratory environment, and that 
the sensitivity of the test was low [Orita et al., 1989].  DHLPC was presented as an 
alternative method, as it had improved sensitivity, provided higher throughput options 
than SSCP, and the preparation, run and analysis of the experiments were relatively short 
[O'Donovan et al., 1998].  The individual loading of samples was bypassed with a semi-
automated plate analysis system. 
Capillary electrophoresis DNA sequencing is the current gold standard for 
mutational screening of HPE genes, with its primary advantage being close to 100% 
sensitivity and specificity.  However, data analysis is labor intensive and challenging 
given the presence of ambiguities that may occur in the chromatograms, as well as allelic 
drop-out and failure to detect deletions/duplications that are larger than the sequence 
being interrogated.  Although DNA sequencing is more readily available than other 
technologies, and it can be used with equal success on both medically-indicated and 
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research-only genetic tests, there is still a strong need for newer methods given the 
extensive heterogeneity of causative HPE genes. 
Multiplex ligation-dependent probe amplification (MLPA) (MRC-Holland, 
Amsterdam) is a relatively new molecular method to detect the occurrence of micro 
deletions/duplications in genes.  There is a panel commercially available (SALSA MLPA 
kit P187 Holoprosencephaly – MCR-Holland, Amsterdam, Netherlands) with probes 
spanning the HPE genes [Bendavid et al., 2009].  Among the limitations of this method 
are that it is available in only a few laboratories, a follow-up test is necessary to validate 
presence of the loss/gain of dosage (e.g. qPCR), and it is unable to detect single 
nucleotide mutations or smaller deletions or duplications.  There is sufficient evidence in 
the literature of an overwhelming number of single nucleotide mutations or small 
deletions/duplications causing truncated proteins.  For example, in a recent study on 
patients with HPE and alterations in SHH, there were 125 different mutations in 
individuals with holoprosencephaly tabulated [Roessler et al., 2009a].  Hence, copy 
number variations and hypothetical promoter or enhancer variations are likely to be 
among the least common types of variations that are likely to be detected. 
High-resolution DNA melting (HRM) strategies have recently been proposed to 
pre-screen samples for mutations [Reed et al., 2007].  In our experience, amplicons from 
many individuals can be simultaneously screened from genomic DNA in roughly two 
hours, followed by direct sequencing of a targeted subset of presumed variants.  This 
method promises considerable savings in terms of money and time in the identification of 
variants.  Some of its greatest advantages are that it has high sensitivity and, specificity, 
(over 95% for heterozygous variants) [Wittwer, 2009] and the high throughput nature it 
American Journal of Medical Genetics Part C (Seminars in Medical Genetics) 
 
14 
allows up to 384 samples to be screened per run, in a Roche LightCycler 480 II 
instrument (Roche Appplied Science, Indianapolis, IN and Idaho Technology Inc., Salt 
Lake City, UT).  As with any new technology, there are also disadvantages. HRM loses 
efficacy with screening GC-rich amplicons due to the difficulty in denaturing them.  
However, denaturing solutions, such as Roche GC-RICH solution (Roche applied 
science, Indianapolis, IN), can be added to enhance the melting process to increase the 
specificity [Tindall et al., 2009]. Moreover, current protocols recommend that amplicons 
be limited in size, up to 400 base pairs [Wittwer, 2009]. 
Next-Generation (NextGen) sequencing strategies and array-CGH (aCGH) offer 
the promise of great amounts of information [Bejjani and Shaffer, 2006; Mardis, 2008] 
although it is not yet clear which of the many new methods will emerge as the most 
useful.  With both of these new strategies, the interpretation of results should be made 
carefully, since miscalling of normal variants as mutations presents the risk of 
misinterpretation. Currently, there is not enough evidence from well-controlled studies to 
unambiguously differentiate disease-causing alterations from incidental copy number 
variants except for the ones involved in the known HPE genes [Bendavid et al., 2009].  
Further research use should help to mitigate these obstacles.  Since these techniques are 
so new and rapidly changing, most of the technologies have not been FDA approved for 
routine clinical use, nevertheless, they are currently used by commercial diagnostic 
laboratories, such as GeneDx (Gaithersburg, MD, USA) for the diagnostic studies of 
several diseases.  Array-CGH may not be appropriate for use on a routine basis until there 
is a better understanding of the implications of copy number variants (CNVs) in the 
pathogenesis of HPE.  As with all detection methods, presumptive positive results should 
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be followed up by family studies, since occurrence of novel events are more likely to be 
pathogenic. 
New technologies, such as HRM, aCGH and NextGen Sequencing, will allow for 
the generation of large amounts of data with sensitivities and specificities over 90%, the 
ability to detect CNVs that we were not able to previously identify, and for the routine 
screening of more genes and regulatory elements to be both cheaper and faster.  
However, the generation of such overwhelming amounts of data by itself does not always 
translate into a better understanding of a disorder. Consequently, the application of these 
tests in a clinical context is presently limited [Bejjani and Shaffer, 2006]. 
We recommend the formation of a worldwide consortium, where research data, 
DNA samples and cell lines would be shared between the largest possible number of 
active investigators involved on HPE research, in order to accomplish an integration of 
knowledge which would contribute to a thorough understanding of the clinical and 
genetic aspects of this disease.  While no such formal organization yet exists, the 
rationale for such an effort is clear.  The extensive genetic heterogeneity of HPE and the 
unresolved issues underlying its characteristic variable expressivity compel researchers in 
this field to cooperate with one another and to enlist the cooperation of primary care 
providers, patient groups and families in this effort.  Some of the obvious future 
challenges of this proposed group will be to collect cases for large-scale studies (e.g. to 
establish routine functional studies based on animal or cellular models, perform family-
based association studies, and case-control association studies) to dissect the genomic 
variants that impact on HPE incidence and severity.  Large datasets increase the statistical 
power of such studies and enhance the certitude of the interpretations. Such an approach, 
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in combination with the technologies mentioned above, should allow, in the future, the 
expansion of a more comprehensive genetic testing strategy of patients with the HPE 
phenotypic spectrum and their relatives. 
 Finally, all of these considerations contribute to difficulties in counseling families 
with HPE [see Odent, this issue].  The extreme heterogeneity and diverse manifestations 
of HPE presents considerable challenges to medical geneticists and counselors.  No 
single algorithm is presently sufficient to explain all cases of HPE.  However, we hope 
that by providing a guideline for the busy clinician we can inspire the genetics 
community to engage in fostering important research in this area.  The sharing of cases 
and case materials should maximize the ability of clinicians to provide meaningful results 
to their patients for the present, as new technologies offer the future promise of an even 
greater understanding of this complex set of malformations. 
  
SUMMARY 
In summary, our current recommendations of medically indicated genetic testing 
of families with HPE are: cytogenetic studies as the first layer of the algorithm (see 
review by Bendavid et al., this issue), since cytogenetic abnormalities make up the most 
common causes of HPE.  Molecular testing of SHH, SIX3 and ZIC2 are the second layer 
of evaluation, since they explain at least 20% of non-syndromic and non-chromosomal 
HPE.  Other genes identified in HPE should be tested as complementary studies in 
special cases, given their low frequency (~1% or less).  These steps should take place in 
the context of a discussion about whether to pursue commercial lab testing and/or 
enrollment in a research study. 
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Table I. 
 
Use Method Advantages Disadvantages 
Past 
SSCP 
 A popular, rapid, inexpensive 
screen for nucleotide variants 
 Detects presence of normal and 
variant alleles 
 Heterozygous vs. homozygous 
results obvious 
 Lowest sensitivity and 
specificity 
 Small amplicons 
 Use of acrylamide gels 
and radioactivity 
 Requires confirmation 
with sequencing 
dHLPC 
 Semi-automated 
 Higher throughput capacity and 
sensitivity than SSCP 
 Requires less time and labor than 
SSCP 
 Improved cost profile 
 Specificity still marginal 
 Requires confirmation 
with sequencing  
Present 
Automated capillary 
DNA sequencing 
 Gold Standard 
 ~100% sensitivity and specificity 
 Semi-automated 
 High throughput capacity 
 Requires significant 
investigator edits 
 Ambiguities frequent, 
occult allelic drop  
 Typically fails to detect 
large deletions or 
duplications  
HRM 
 Effective screening method 
 High throughput 
 Sensitivity over 90% 
 Specificity excellent and improves 
with increased throughput 
 Post-PCR manipulation is not 
required 
 Fast automatic run where the 
analysis can focus on sequencing 
the uncommon variants flagged 
by the software 
 
 Screening of some GC-
rich regions can be 
challenging 
 Optimal results with 
small amplicons ~300 bp 
 Requires follow-up 
sequencing of variants 
MLPA 
 Fast and high throughput method 
 Detects sub-microscopic 
deletions/duplications missed by 
sequencing 
 Typically requires 
validation studies 
 Few laboratories 
perform test  
Array-CGH 
 Capable of detection of genome 
wide gains/losses of copy 
 Requires no hypothesis 
 Expensive 
 Validation with another 
method often needed 
 Only large scale changes 
 Needs several 
micrograms of DNA 
Future 
Next-Generation 
Sequencing 
 Capable of genome-wide 
individualized data 
 High tiling path = few errors 
 Unambiguous results 
 Relatively fast  
 In development on 
multiple platforms 
 Huge amounts of data 
(almost all of which is 
normal) 
 Significance of most 
variants will initially not 
be understood 
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Figure 1. Algorithm for the genetic study of new holoprosencephaly patients:  Bold 
lines refer to medically indicated tests; thin lines are optional tests depending on a 
specific clinical indication or the capabilities of the diagnostic laboratory; dotted lines 
refer to tests available in research labs that will contribute to a better understanding of 
HPE.  For further details, see the following references: a: [Hahn et al.,this issue; [Hahn 
and Plawner, 2004] b: [Dubourg et al., 2007] c: [Roessler and Muenke, this issue] d: 
[Bendavid et al., this issue] e: Refers to High-Resolution DNA Melting (HRM) f: 
Multiplex Ligation-dependent Probe Amplification (MLPA) g: gene specific phenotype, 
h: [Bullen et al., 2001; Ong et al., 2007].   
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